The bull case for LQDA: YUTREPIA can keep generating PAH revenue, while L606 could offer another path into PH-ILD if trials and review succeed.
Detailed price information for Xenon Pharmaceuticals Inc (XENE-Q) from The Globe and Mail including charting and trades.
Liquidia shares rise 7% after Q3 YUTREPIA sales climb 31% sequentially to $222.7 million and it settles its United Therapeutics dispute.
LQDA's Q3 results will spotlight the impact of its legal settlement with UTHR, cash flow pressures, profitability prospects and pipeline progress.
Detailed price information for Boston Scientific Corp (BSX-N) from The Globe and Mail including charting and trades.
Detailed price information for Liquidia Corp (LQDA-Q) from The Globe and Mail including charting and trades.
Liquidia (LQDA) surges after settling United Therapeutics litigation, lifting uncertainty around YUTREPIA.
Gainers MaxCyte (NASDAQ:MXCT) shares rose 34.5% to $1.3 during Wednesday's regular session. The company's market cap stands at $102.6 million. Liquidia (NASDAQ:LQDA) stock moved upwards by 26.29% to $33.86.
Liquidia (LQDA) stock surges as the company settles all lawsuits with United Therapeutics (UTHR), prompting BTIG to upgrade the firm. Read more here.
Shares of Liquidia surged nearly 30% this morning after the company settled six lawsuits with rival United Therapeutics, ending multiyear litigation that had threatened to restrict sales of Liquidia's main drug, called Yutrepia. Morrisville, N.C.-based Liquidia said it will pay around $380 million
U.S. stocks mostly fell, but Bending Spoons surged 40% after Berkshire’s $330M investment. Liquidia and Verastem also posted strong gains.
Liquidia stock soared Wednesday on settlement deal with United Therapeutics that allows its drug to stay on the market.
Liquidia surges after reaching a $380.7 million settlement with United Therapeutics resolving patent disputes for its lung disease drug.
Gainers Liquidia (NASDAQ:LQDA) shares moved upwards by 41.0% to $37.8 during Wednesday's pre-market session. The market value of their outstanding shares is at $2.4 billion. Greenland Mines (NASDAQ:GRML) shares
This is the newest page. Registered accounts read further back.